Health Care Cost

Integrated primary care services may offer better outcomes in patients living with severe chronic obstructive pulmonary disease (COPD) without increasing costs.

Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.

New and emerging medications in the specialty drug pipeline were discussed during a keynote address at AMCP Nexus 2022 by Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, with biosimilars, orphan drugs, and cell and gene therapies emerging as key trends to watch.

On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

Investigators for this study analyzed outcomes among patients hospitalized with pulmonary arterial hypertension (PAH) who have higher risks of adverse health outcomes, in particular sepsis and septic shock.

With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.

Svante Pääbo was awarded the Nobel Prize in Physiology or Medicine for his discoveries in human evolution; the amyotrophic lateral sclerosis (ALA drug AMX0035 was priced at $158,000 per year or about $12,500 per 28-day prescription; more than 16,000 Americans died of combination cancer and COVID-19 in the first 10 months of the pandemic.

A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.

The presentation focused on the Protocol AC trial, which considered whether step therapy had an impact on visual outcomes for patients starting on bevacizumab and switching to aflibercept later.

A recent study suggests that including a pharmacist in the hemophilia comprehensive care model may improve bleeding outcomes and medication access and adherence, and lead to cost savings.

A panel discussion at the 70th Annual Roy A. Bowers Pharmaceutical Conference addressed recent care delivery initiatives in New Jersey that aim to address health inequities and other population health concerns.

Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

As health care shifts reimbursement models from fee-for-service to value-based care, new terms and phrases have been surfacing across the industry. Two of the terms emerging with increased usage are “patient engagement” and an “active patient.” But what do they mean? And why are they important?

On this episode of Managed Care Cast, we speak with 2 authors of an article in the September issue of The American Journal of Managed Care®, which focused on the results of their evaluation of an intensive, community-based care management program for dual-eligible Medicaid ACO high-risk patients.

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.

Streamlining the prior authorization process can improve care accuracy and patient access to care, writes Siva Namasivayam, CEO of Cohere Health.

A recent study found that 1 in 5 households were strapped with medical debt; hospitals and hospital systems in North Carolina proposed a way to expand Medicaid to hundreds of thousands of adults; the CDC reported that more adults sought mental health treatment in 2021 compared with 2019.

Nearly 30% of youths are affected with worsening mental health by the end of adolescence, with anxiety typically presenting in childhood and depression during the teenage years, but the problem is even more acute for Black and Latinx youth.

The retrospective claims database analysis looked at patients in the United States, where it is estimated that costs related to asthma are more than $80 billion annually.

Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.

Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

Patients with diabetes and chronic obstructive pulmonary disease (COPD) have worse outcomes when hospitalized and appear to be more vulnerable to respiratory and nonrespiratory complications after a COPD exacerbation, which highlights the need for targeted interventions in this population.

The authors modeled costs associated with a pedometer-based, web-mediated physical activity intervention compared with a pedometer alone for chronic obstructive pulmonary disease (COPD) management. The intervention was cost-saving.

In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.